Biomarkers in COPD: Time for a Deep Breath

Overview

Journal Thorax

Date 2007 Aug 10

PMID 17687095

Citations 7

Authors

R A Stockley

Affiliations

Soon will be listed here.

Citing Articles

Common Strategies and Factors Affecting Off-Line Breath Sampling and Volatile Organic Compounds Analysis Using Thermal Desorption-Gas Chromatography-Mass Spectrometry (TD-GC-MS).

Westphal K, Dudzik D, Waszczuk-Jankowska M, Graff B, Narkiewicz K, Jan Markuszewski M Metabolites. 2023; 13(1).

PMID: 36676933 PMC: 9866406. DOI: 10.3390/metabo13010008.

Serum immunoglobulin free light chain levels in systemic autoimmune rheumatic diseases.

Gulli F, Napodano C, Marino M, Ciasca G, Pocino K, Basile V Clin Exp Immunol. 2019; 199(2):163-171.

PMID: 31618438 PMC: 6954672. DOI: 10.1111/cei.13385.

Defining phenotypes in COPD: an aid to personalized healthcare.

Segreti A, Stirpe E, Rogliani P, Cazzola M Mol Diagn Ther. 2014; 18(4):381-8.

PMID: 24781789 DOI: 10.1007/s40291-014-0100-9.

Transforming growth factor-β1 and tumor necrosis factor-α are associated with clinical severity and airflow limitation of COPD in an additive manner.

Chiang C, Chuang C, Liu S Lung. 2013; 192(1):95-102.

PMID: 24153451 DOI: 10.1007/s00408-013-9520-2.

The expanding role of biomarkers in the assessment of smoking-related parenchymal lung diseases.

Doyle T, Pinto-Plata V, Morse D, Celli B, Rosas I Chest. 2012; 142(4):1027-1034.

PMID: 23032451 PMC: 3465104. DOI: 10.1378/chest.12-1540.

References

Stockley R . Neutrophils and protease/antiprotease imbalance. Am J Respir Crit Care Med. 1999; 160(5 Pt 2):S49-52. DOI: 10.1164/ajrccm.160.supplement_1.13. View

Fogarty A, Jones S, Britton J, Lewis S, McKeever T . Systemic inflammation and decline in lung function in a general population: a prospective study. Thorax. 2007; 62(6):515-20. PMC: 2117221. DOI: 10.1136/thx.2006.066969. View

Ridker P, Rifai N, Rose L, Buring J, Cook N . Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002; 347(20):1557-65. DOI: 10.1056/NEJMoa021993. View

Stewart C, Newcomb P, Holly J . Multifaceted roles of TNF-alpha in myoblast destruction: a multitude of signal transduction pathways. J Cell Physiol. 2003; 198(2):237-47. DOI: 10.1002/jcp.10387. View

Churg A, Wang R, Tai H, Wang X, Xie C, Wright J . Tumor necrosis factor-alpha drives 70% of cigarette smoke-induced emphysema in the mouse. Am J Respir Crit Care Med. 2004; 170(5):492-8. DOI: 10.1164/rccm.200404-511OC. View

Rana J, Mittleman M, Sheikh J, Hu F, Manson J, Colditz G . Chronic obstructive pulmonary disease, asthma, and risk of type 2 diabetes in women. Diabetes Care. 2004; 27(10):2478-84. DOI: 10.2337/diacare.27.10.2478. View

Hotamisligil G, Peraldi P, Budavari A, Ellis R, White M, Spiegelman B . IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science. 1996; 271(5249):665-8. DOI: 10.1126/science.271.5249.665. View

Li Y, Schwartz R, Waddell I, Holloway B, Reid M . Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kappaB activation in response to tumor necrosis factor alpha. FASEB J. 1998; 12(10):871-80. DOI: 10.1096/fasebj.12.10.971. View

Gianni W, Ricci A, Gazzaniga P, Brama M, Pietropaolo M, Votano S . Raloxifene modulates interleukin-6 and tumor necrosis factor-alpha synthesis in vivo: results from a pilot clinical study. J Clin Endocrinol Metab. 2004; 89(12):6097-9. DOI: 10.1210/jc.2004-0795. View

10.

Bolton C, Ionescu A, Shiels K, Pettit R, Edwards P, Stone M . Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004; 170(12):1286-93. DOI: 10.1164/rccm.200406-754OC. View

11.

Pai J, Pischon T, Ma J, Manson J, Hankinson S, Joshipura K . Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004; 351(25):2599-610. DOI: 10.1056/NEJMoa040967. View

12.

Sin D, Paul Man S . Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc. 2005; 2(1):8-11. DOI: 10.1513/pats.200404-032MS. View

13.

Donaldson G, Seemungal T, Patel I, Bhowmik A, Wilkinson T, Hurst J . Airway and systemic inflammation and decline in lung function in patients with COPD. Chest. 2005; 128(4):1995-2004. PMC: 7172405. DOI: 10.1378/chest.128.4.1995. View

14.

Jain M, Ridker P . Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov. 2005; 4(12):977-87. DOI: 10.1038/nrd1901. View

15.

Franciosi L, Page C, Celli B, Cazzola M, Walker M, Danhof M . Markers of disease severity in chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2005; 19(3):189-99. DOI: 10.1016/j.pupt.2005.05.001. View

16.

de Torres J, Cordoba-Lanus E, Lopez-Aguilar C, Muros de Fuentes M, Montejo de Garcini A, Aguirre-Jaime A . C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J. 2006; 27(5):902-7. DOI: 10.1183/09031936.06.00109605. View

17.

Sevenoaks M, Stockley R . Chronic Obstructive Pulmonary Disease, inflammation and co-morbidity--a common inflammatory phenotype?. Respir Res. 2006; 7:70. PMC: 1479815. DOI: 10.1186/1465-9921-7-70. View

18.

Man S, Connett J, Anthonisen N, Wise R, Tashkin D, Sin D . C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax. 2006; 61(10):849-53. PMC: 2104755. DOI: 10.1136/thx.2006.059808. View

19.

Parr D, White A, Bayley D, Guest P, Stockley R . Inflammation in sputum relates to progression of disease in subjects with COPD: a prospective descriptive study. Respir Res. 2006; 7:136. PMC: 1664562. DOI: 10.1186/1465-9921-7-136. View

20.

Dahl M, Vestbo J, Lange P, Bojesen S, Tybjaerg-Hansen A, Nordestgaard B . C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006; 175(3):250-5. DOI: 10.1164/rccm.200605-713OC. View